Enzyme inhibitors are naturally occurring molecules that attach to the enzymes to inhibit the culture of harmful pathogens and enhance metabolism. They have varied applications as drugs in therapeutics and pesticides for agricultural activities. In recent years, the market has witnessed significant growth owing to outsourcing manufacturing process coupled with effective & accurate therapies for chronic diseases such as cancer, respiratory diseases, and others.
This report projects the global enzyme inhibitors market with trends, opportunities, and its demand by 2022. This research includes qualitative & quantitative analyses with comprehensive research methodologies and reliable forecasts to create the present overview of the market and predict the market during the forecast period. Our research teams have used various secondary resources & directories such as industrial databases, journals & magazine, along with primary resources, coupled with industry-oriented measures, such as industry-related expert interviews, to obtain key information and valuables.
Inactive lifestyle, unhealthy dietary plans, and excessive alcohol consumption and smoking have resulted in a significant rise in diseases such as inflammatory lungs, cancer, hypertension & respiratory infections. These factors have paved the way for the market to grow, with effective treatments and reduced infection rates. Proton pump inhibitors registered notable growth owing to increase in gastroesophageal reflux treatments followed by protease inhibitors in HIV medications. Kinase & aromatic inhibitors are expected to witness lucrative growth owing to their application in cancerous cells. Europe has dominated the enzyme inhibitors market, supplemented with developments in healthcare and investment in R&D. Asia-Pacific followed by LAMEA are estimated to be potential market drivers owing to increase in pharmaceutical establishments and agricultural activities. Patent expirations of enzyme inhibitors and low-cost generics adversely affect the revenue generation; however, development of healthcare infrastructure and novel inhibitors is expected to provide a significant boost to market growth.
The enzyme inhibitors market is segmented based on type, application, and geography. Based on type, it includes proton pumps inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and others. According to application, it is categorized into chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key players operating in this market include AstraZeneca, GlaxoSmithKline, Bayer, Novartis, Roche & Pfizer, Ranbaxy Laboratories, Johnson & Johnson, Abbott Laboratories Inc., and Takeda.
KEY BENEFITS FOR STAKEHOLDERS:
- This report provides a quantitative analysis of the current trends, future estimations, clinical developments, and dynamics through 20142022, which assist in identifying the market behavior and prevailing opportunities.
- Major countries in each region are mapped as per individual market revenue.
- This study takes into account the competitive landscape and value chain to understand the competitive environment across the geographies.
- Comprehensive analysis of factors that drive and restrict the growth of the enzyme inhibitors market is provided.
- Leading players and their key developments in recent years are listed.
KEY MARKET SEGMENTS:
- Proton Pump Inhibitors (PPIs)
- Protease Inhibitors
- Reverse Transcriptase Inhibitors
- Aromatase Inhibitors
- Kinase Inhibitors
- Neuraminidase Inhibitors
- Cardiovascular Treatments
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Middle East
- South Africa
- Rest of LAMEA